Late-stage biopharma Scholar Rock (SRRK) is approaching a pivotal catalyst: the FDA decision on apitegromab, its investigational muscle-targeted therapy for spinal muscular atrophy (SMA). A verdict is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback